Peregrine Pharmaceuticals, Inc. to Present at Lazard Healthcare Conference November 15, 2011 at 11:30 AM EST

TUSTIN, CA--(Marketwire - November 08, 2011) -

Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced it will present at the 8th Annual Lazard Capital Markets Healthcare Conference in New York, NY on Tuesday, November 15, 2011 at 11:30 AM EST.

Peregrine’s presentation will be webcast live and available for replay until November 29, 2011 at: http://ir.peregrineinc.com/events.cfm

For more information about this conference, please visit: http://www.lazardcap.com/conferenceList.aspx?tn=4&ln=3&itm=3579&lid=1901

About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Digg this Bookmark with del.icio.us Add to Newsvine

Technorati: Peregrine Pharmaceuticals Lazard bavituximab immunotherapy antibody cancer phosphatidylserine